693 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/765897/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-765897 Feb 14, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-ZC-FT-analyst_blog|stock_roundup-765605 Feb 14, 2020 - AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema https://www.fool.com/investing/2020/02/12/eli-lilly-and-incyte-record-another-positive-clini.aspx?source=iedfolrf0000001 Feb 12, 2020 - The drug moves closer to an expanded approval for the skin disorder.
Lilly Reports Disappointing Data on Alzheimer's Candidate http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760082 Feb 11, 2020 - Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-754447 Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong http://www.zacks.com/stock/news/752611/sanofi-sny-q4-earnings-top-sales-miss-dupixent-strong?cid=CS-ZC-FT-analyst_blog|earnings_article-752611 Feb 06, 2020 - Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Top Research Reports for Netflix, Eli Lilly & United Parcel Service http://www.zacks.com/research-daily/750463/top-research-reports-for-netflix-eli-lilly-united-parcel-service?cid=CS-ZC-FT-research_daily-750463 Feb 05, 2020 - Top Research Reports for Netflix, Eli Lilly & United Parcel Service
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748888 Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-ZC-FT-stocks_in_the_news|major_headlines-747608 Feb 03, 2020 - Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Eli Lilly Launches a New Migraine Drug https://www.fool.com/investing/2020/01/31/lilly-launches-a-new-migraine-drug.aspx?source=iedfolrf0000001 Jan 31, 2020 - Reyvow is the first drug in an entirely new class of acute migraine treatments.

Pages: 123456...70

Page 1>